Get the app
NSEHealthcare

Gufic Biosciences Limited (GUFICBIO)

NSE · Healthcare · Drug Manufacturers - Specialty & Generic

₹425.50+1.35%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
₹261 cr
Revenue YoY
+16.6%
Net profit
₹22 cr
Profit YoY
+70.7%
EPS
₹0.51
EPS estimate
₹0.61
Net margin
8.6%

EPS came in at 0.51 against a street estimate of 0.61 — a miss of 16.4%.

Key statistics

Market cap
₹4,263 cr
P/E
58.2
Forward P/E
0.0
P/B
6.41
Book value
₹66.31
EPS (TTM)
₹7.31
52-week high
₹453.95
52-week low
₹267.94
50-day MA
₹407.60
200-day MA
₹339.48
Beta
-0.04

Shareholding

Promoters
77.50%
Institutions
3.55%

Recent filings & reports

DocumentDate
Q1 FY27 earnings call
GUFIC BIOSCIENCES LIMITED – Q1 FY27 SUMMARY HEADLINE NUMBERS • Total revenue from operations Q1 FY27: INR 260.8 crores (vs INR 226.9 crores in Q1 FY
2026-08-21
Investor presentation · Q1 FY27
GUFIC BIOSCIENCES LIMITED – Q1 FY27 INVESTOR SUMMARY HEADLINE NUMBERS • Total Revenue Q1 FY27: Rs 260.8 crore (up from Rs 226.9 crore in Q1 FY26; +1
2026-08-14
Quarterly results · Q1 FY27
GUFIC BIOSCIENCES LIMITED – QUARTERLY RESULTS SUMMARY Q1 FY2026-27 (Quarter Ended June 30, 2026) --- HEADLINE NUMBERS • Revenue from operations (St
2026-08-14
Annual report FY2026
GUFIC BIOSCIENCES LIMITED – FY 2025-26 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue from Operations (Standalone): ₨94,047.53 Lakhs in FY
2026-08-12
Quarterly results · Q4 FY26
GUFIC BIOSCIENCES LIMITED – FINANCIAL RESULTS SUMMARY Year Ended March 31, 2026 --- HEADLINE NUMBERS • Total Revenue (Standalone): Rs. 94,047.54 la
2026-05-29
Q3 FY26 earnings call
DOCUMENT SUMMARY: GUFIC BIOSCIENCES LIMITED HEADLINE NUMBERS • No financial figures, revenue, earnings, or performance metrics provided in this docum
2026-02-20
Quarterly results · Q3 FY26
GUFIC BIOSCIENCES LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • Q3 FY2026 Revenue (Standalone): Rs. 23,109.36 lakhs • 9M FY2026 Revenue (Standalone)
2026-02-13
Investor presentation
GUFIC BIOSCIENCES LIMITED – Q3 FY26 INVESTOR SUMMARY --- HEADLINE NUMBERS • Q3 FY26 Total Revenue: Rs 231.1 crore (vs Rs 230.4 crore in Q2 FY26; vs
2026-02-13

Readable in the app.

Corporate actions

ActionDetailDate
Dividend₹0.10 / share
ex-date Aug 28, 2026
2026-08-28
Dividend₹0.10 / share
ex-date Sep 22, 2025
2025-09-22

Deals & corporate news

AnnouncementDate
Acquisition of another business completed
Gufic Biosciences Limited, an Indian pharmaceutical company, announced Board approval on August 14, 2026 to incorporate a new subsidiary in the Philippines called Gufic Philippines Inc. The
2026-08-14
Further investment in Saraswat Co-operative Bank Limited
Gufic Biosciences Limited has informed the Exchange about further investment in Saraswat Co-operative Bank Limited
2026-05-29
Acquisition of Gufic Biosciences Limited announced
Gufic Biosciences Limited has informed the Exchange about Acquisition
2026-02-13

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Gufic Biosciences Limited — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.